DLGAP1 Antibody

What is the biological function of DLGAP1 in neuronal systems?

DLGAP1/GKAP is a scaffold protein localized to the postsynaptic density that serves as a key adaptor protein of NMDA receptors. It plays critical roles in signaling to and from glutamate receptors, learning and memory processes, and synaptic plasticity in the central nervous system . As part of the DLGAP family (which comprises five conserved proteins, DLGAP1–DLGAP5), DLGAP1 interacts directly with both DLG and SHANK proteins through multiple domains, forming essential components of the postsynaptic protein network . This molecular architecture enables DLGAP1 to function as a crucial organizational element within excitatory synapses, particularly in glutamatergic neurons where it is highly expressed.

How does DLGAP1 relate to neuropsychiatric disorders?

Genetic studies have established significant associations between DLGAP1 variants and several neuropsychiatric conditions. Gain-of-function variants of DLGAP1 have been associated with obsessive-compulsive disorder (OCD), while haploinsufficient variants have been linked to autism spectrum disorder (ASD) and schizophrenia . The first Genome Wide Association Study for OCD identified two single nucleotide polymorphisms with the lowest P-values located within a DLGAP1 intron, and a 63 kb duplication of four DLGAP1 exomes was observed in siblings with pediatric OCD . Conversely, de novo deletion CNVs and rare protein-altering variants of DLGAP1 have been identified in schizophrenia and ASD cases, suggesting that both overexpression and underexpression of this protein can contribute to distinct neuropsychiatric phenotypes .

What is the difference between DLGAP1 and DLGAP1-AS1?

While their names suggest a relationship, DLGAP1 and DLGAP1-AS1 represent distinct molecular entities with different functions. DLGAP1 encodes a protein involved in neuronal signaling at the postsynaptic density . In contrast, DLGAP1-AS1 (DLGAP1 antisense RNA 1) is a long noncoding RNA located on chromosome 18p11.31 that has been implicated in various cancers . In glioma, for example, DLGAP1-AS1 has been found to be upregulated in both tissue samples and cell lines, promoting invasion, migration, and proliferation of cancer cells through its function as a miR-1297 sponge . This long noncoding RNA appears to modulate the miR-1297/EZH2 axis, supporting glioma progression through molecular mechanisms distinct from the neuronal functions of DLGAP1 protein .

What are the optimal conditions for using anti-DLGAP1 antibodies in Western blot applications?

For Western blot analysis of DLGAP1 expression in brain tissues, researchers should use freshly prepared lysates from mouse or rat brain samples. The recommended dilution for anti-DLGAP1/GKAP antibody (such as APZ-041) is 1:200 . Protein separation should be performed using standard SDS-PAGE techniques with appropriate molecular weight markers to identify the DLGAP1 band. When analyzing brain lysates, ensure proper sample preparation to minimize protein degradation, which can affect antibody recognition. The antibody has been validated to recognize DLGAP1 from human, mouse, and rat samples, making cross-species comparative studies feasible . For optimal results, use appropriate positive controls (wild-type brain tissue) and negative controls (DLGAP1 knockout tissue if available) to validate antibody specificity.

How should immunohistochemical staining for DLGAP1 be optimized in brain tissue sections?

Immunohistochemical detection of DLGAP1 requires careful tissue preparation and staining optimization. For brain sections, perfusion-fixed frozen tissue preparations yield the best results for preserving DLGAP1 antigenicity and cellular architecture . The recommended protocol involves using anti-DLGAP1/GKAP antibody at a 1:200 dilution, followed by appropriate secondary antibody detection (e.g., goat anti-rabbit-AlexaFluor-488) . DLGAP1 staining is particularly prominent in neuronal structures, such as the hippocampal CA3 pyramidal layer, where it appears as punctate labeling consistent with its localization to postsynaptic densities . Counterstaining with DAPI allows visualization of neuronal cell bodies in relation to DLGAP1 expression. When optimizing the protocol, consider incorporating antigen retrieval steps if initial staining appears weak, and ensure sufficient blocking to minimize background fluorescence.

What experimental approaches can be used to study DLGAP1 function in neuronal systems?

Multiple complementary approaches can effectively investigate DLGAP1 function in neurons:

• Genetic manipulation models: DLGAP1 knockout mice provide valuable insights into protein function, revealing disruptions in PSD protein interactions and deficits in sociability . Both homozygous and heterozygous models should be examined to understand gene dosage effects.

• Biochemical fractionation: Subcellular fractionation of brain tissue can isolate postsynaptic density components, allowing examination of DLGAP1's interaction partners using co-immunoprecipitation and Western blotting .

• High-resolution imaging: Super-resolution microscopy combined with DLGAP1 immunostaining can visualize its precise localization within the postsynaptic architecture and its spatial relationship with interacting proteins.

• Electrophysiology: Patch-clamp recordings in wild-type versus DLGAP1-manipulated neurons can reveal functional consequences of altering DLGAP1 expression on synaptic transmission and plasticity.

• Behavioral testing: A battery of behavioral tests (including social approach, prepulse inhibition, and cognitive tasks) can assess the impact of DLGAP1 manipulation on behaviors relevant to associated neuropsychiatric disorders .

How can researchers study the molecular interactions between DLGAP1 and other postsynaptic density proteins?

Investigating DLGAP1's interactions with other PSD proteins requires sophisticated molecular approaches:

• Co-immunoprecipitation (Co-IP): Using anti-DLGAP1 antibodies to pull down protein complexes from brain lysates, followed by Western blotting for potential interacting partners (particularly DLG and SHANK family proteins) . This technique can identify stable protein-protein interactions within the postsynaptic density.

• Proximity ligation assay (PLA): This technique can visualize protein-protein interactions in situ by generating fluorescent signals when two proteins are in close proximity (<40 nm). Combining anti-DLGAP1 antibodies with antibodies against suspected interacting partners can map interaction networks within intact neurons.

• Yeast two-hybrid screening: This approach can identify novel DLGAP1 binding partners by testing for protein interactions in a yeast expression system, potentially revealing previously unknown components of DLGAP1-containing complexes.

• Mass spectrometry analysis: Following immunoprecipitation with anti-DLGAP1 antibodies, mass spectrometry can identify both known and novel interacting proteins in an unbiased manner, providing a comprehensive view of the DLGAP1 interactome.

• FRET (Förster Resonance Energy Transfer): By tagging DLGAP1 and potential binding partners with appropriate fluorophores, researchers can detect direct protein interactions through energy transfer mechanisms in living neurons.

What approaches can detect alterations in DLGAP1 expression in disease models?

To effectively measure DLGAP1 expression changes in disease contexts:

• Quantitative Western blotting: Using anti-DLGAP1 antibodies with appropriate normalization controls (such as GAPDH or β-actin) allows for precise quantification of protein levels in tissue samples from disease models compared to controls .

• qRT-PCR: Although not directly utilizing antibodies, this technique complements protein analysis by quantifying DLGAP1 mRNA expression, which may reveal transcriptional dysregulation preceding protein changes.

• Immunohistochemical quantification: Standardized immunohistochemistry protocols with anti-DLGAP1 antibodies, followed by quantitative image analysis, can measure changes in protein expression and localization in specific brain regions and cell types .

• Single-cell analysis: Combining immunofluorescence for DLGAP1 with markers for specific cell types can reveal cell-specific alterations in protein expression that might be masked in whole-tissue analyses.

• Proteomics approaches: Mass spectrometry-based proteomics of synaptic fractions can provide unbiased quantification of DLGAP1 alongside hundreds of other synaptic proteins, placing DLGAP1 changes within the broader context of synaptic proteome alterations.

How do DLGAP1 knockout models inform our understanding of postsynaptic organization?

DLGAP1 knockout mice have provided critical insights into this protein's role in postsynaptic architecture:

• Disruption of protein complexes: Biochemical studies in DLGAP1 KO mice reveal significant disruption of protein interactions within the postsynaptic density, confirming DLGAP1's role as a critical organizational scaffold .

• Behavioral phenotypes: DLGAP1 KO mice exhibit deficits in sociability while other behavioral measures remain largely unaffected, suggesting a selective impact on social behavior circuits consistent with DLGAP1's association with ASD and schizophrenia .

• Ultrastructural analysis: Electron microscopy combined with immunogold labeling can visualize changes in PSD morphology and protein distribution in the absence of DLGAP1, revealing structural reorganization at the nanoscale level.

• Synaptic protein compensation: Quantitative analysis of other scaffold proteins in DLGAP1 knockout models can reveal compensatory mechanisms that may partially preserve synaptic function, explaining the selective nature of behavioral deficits.

• Electrophysiological consequences: Recordings from DLGAP1 KO neurons can demonstrate how disruption of this scaffold affects synaptic transmission, potentially linking molecular disorganization to functional deficits.

What are common issues when detecting DLGAP1 in brain tissue samples?

Researchers frequently encounter several challenges when working with DLGAP1 antibodies:

• Specificity concerns: Some commercial antibodies may detect additional bands besides DLGAP1. Validation using DLGAP1 knockout tissue as a negative control is essential to confirm specificity .

• Protein degradation: DLGAP1, as a scaffold protein, can be susceptible to proteolytic degradation during sample preparation. Use of fresh tissue, appropriate protease inhibitors, and controlled sample handling is critical for consistent results.

• Fixation artifacts: Overfixation can mask epitopes recognized by anti-DLGAP1 antibodies. Optimization of fixation protocols (duration, fixative concentration) may be necessary for immunohistochemical applications.

• Signal intensity variations: DLGAP1 expression levels vary across brain regions, potentially requiring different antibody concentrations or detection protocols for optimal visualization in different areas.

• Background staining: Non-specific binding can complicate interpretation of results, particularly in immunohistochemistry. Thorough blocking steps and appropriate negative controls (omitting primary antibody) help distinguish specific from non-specific signal.

How can researchers distinguish between DLGAP1 isoforms?

DLGAP1 exists in multiple isoforms, which can complicate experimental interpretation:

• Isoform-specific antibodies: Where available, antibodies targeting unique regions of specific DLGAP1 isoforms provide the most direct approach to distinguishing variants.

• Western blot resolution: High-resolution gel systems can separate closely migrating isoforms based on molecular weight differences, allowing identification of specific variants when combined with appropriate antibody detection.

• RT-PCR analysis: Although not directly using antibodies, PCR with isoform-specific primers can complement protein studies by identifying which isoform transcripts are expressed in the tissue of interest.

• Mass spectrometry: Following immunoprecipitation with anti-DLGAP1 antibodies, mass spectrometry analysis can identify peptides unique to specific isoforms, providing definitive isoform identification.

• Recombinant protein standards: Including purified recombinant DLGAP1 isoforms as standards in Western blot analysis can help identify specific variants based on migration patterns.

What controls should be included when using DLGAP1 antibodies?

Rigorous experimental design requires appropriate controls:

• Positive tissue controls: Brain tissue (particularly cortex and hippocampus) from wild-type animals should show strong DLGAP1 expression in Western blot and immunohistochemistry applications .

• Negative controls:

  • Tissue from DLGAP1 knockout animals provides the gold standard negative control

  • Primary antibody omission controls detect non-specific secondary antibody binding

  • Irrelevant primary antibody controls (same species and concentration) identify non-specific binding

• Antibody validation controls: Pre-absorption of the antibody with its immunizing peptide should eliminate specific staining while leaving non-specific background.

• Loading controls: For Western blotting, appropriate loading controls (GAPDH, β-actin, or total protein staining) must be included to enable accurate quantification.

• Cross-reactivity controls: Testing the antibody on tissues from different species can confirm cross-reactivity claims and help interpret results in comparative studies.

How can DLGAP1 antibodies contribute to understanding the relationship between DLGAP1 and DLGAP1-AS1 in cancer research?

While DLGAP1 and DLGAP1-AS1 represent distinct molecular entities, investigating their potential relationship presents intriguing research opportunities:

• Co-expression analysis: Using anti-DLGAP1 antibodies alongside techniques to detect DLGAP1-AS1 (such as RNA FISH or qRT-PCR) can determine whether there is correlative expression between the protein and the long non-coding RNA in cancer tissues.

• Functional studies: Following manipulation of DLGAP1-AS1 levels (via siRNA knockdown or overexpression), anti-DLGAP1 antibodies can assess whether the lncRNA influences DLGAP1 protein expression or localization.

• Subcellular localization: DLGAP1-AS1 is primarily expressed in the cytoplasm of glioma cells , while DLGAP1 protein localizes to postsynaptic sites in neurons. Immunofluorescence studies with anti-DLGAP1 antibodies in cancer cells could reveal whether the protein shows altered localization in malignant contexts.

• Pathway analysis: Given that DLGAP1-AS1 modulates the miR-1297/EZH2 axis in glioma , researchers can investigate whether this regulatory pathway influences DLGAP1 expression using antibody-based detection methods.

• Clinical correlation studies: Combining DLGAP1 protein quantification (using antibody-based methods) with DLGAP1-AS1 expression analysis in patient samples could reveal clinical correlations and potential prognostic significance.

What methodologies can assess post-translational modifications of DLGAP1?

Post-translational modifications can significantly impact DLGAP1 function:

• Phospho-specific antibodies: Development or utilization of antibodies recognizing specific phosphorylated residues of DLGAP1 can reveal activity-dependent regulation of this scaffold protein.

• Two-dimensional gel electrophoresis: Combining isoelectric focusing with SDS-PAGE, followed by anti-DLGAP1 immunoblotting, can separate differentially modified forms of the protein.

• Mass spectrometry: Following immunoprecipitation with anti-DLGAP1 antibodies, mass spectrometry analysis can comprehensively identify various post-translational modifications, including phosphorylation, ubiquitination, and SUMOylation.

• Phosphatase treatment: Comparing Western blot patterns of DLGAP1 before and after phosphatase treatment can reveal the extent of phosphorylation and its impact on protein mobility.

• Pharmacological manipulation: Treating neurons with kinase activators or inhibitors before immunoblotting with anti-DLGAP1 antibodies can identify signaling pathways regulating DLGAP1 modifications.

How can DLGAP1 antibodies be applied in high-throughput screening approaches?

Adaptation of DLGAP1 antibodies for high-throughput applications offers exciting research possibilities:

• Tissue microarrays: Anti-DLGAP1 antibodies can be used to stain brain tissue microarrays containing samples from multiple patients with neuropsychiatric disorders, enabling rapid screening of expression changes across conditions.

• Automated immunocytochemistry: Robotics-assisted immunostaining with anti-DLGAP1 antibodies in cultured neuron arrays can screen compounds for their ability to modulate DLGAP1 expression or localization.

• ELISA-based detection: Development of sandwich ELISA systems using anti-DLGAP1 antibodies can enable quantitative protein detection in multiple samples simultaneously.

• Reverse phase protein arrays: This technique allows simultaneous analysis of DLGAP1 expression across hundreds of samples using minimal amounts of protein extract and specific antibodies.

• High-content imaging: Combining automated microscopy with anti-DLGAP1 immunofluorescence can quantify protein expression, localization, and co-localization with partners across large numbers of treated neuronal cultures.